Connect with us

BUSINESS

Rapid Dose Therapeutics Corp (OTCMKTS: RDTCF) Announce Q1 2021 Revenue of $131,198

Published

on

Rapid Dose Therapeutics Corp (OTCMKTS: RDTCF) has announced its Q1 2021 financial results for the period ended May 31, 2021. 

Rapid Dose announce Q1 2021 net loss of $0.001 per share

The company reported revenue of $131,198 compared to nil in the same period a year ago. Net loss was $128,623 or $0.001 per share relative to a net loss of $509,972 or $0.01 per basic share. 

CEO Mark Upsdell said, “The Company is on a path of transformation and is well-positioned to drive innovation and our business plan forward as a result of activities that were achieved in this first quarter of 2022. We are well positioned to have a number of exciting COVID-19 vaccine announcements to come with the results from the ongoing McMaster University studies and the launch of our RDT-branded cannabis products on store shelves, among others. We are very pleased with our partners and our team members with their commitment to our success.”

During the quarter, the company entered an exclusive manufacturing and distribution deal with MapleX, which is the company’s Walmart and Amazon partner for online sales. In addition, the company announced Consolidated Craft Brands’ acquisition and amalgamation on March 19, 2021. 

Rapid Dose Therapeutics reported 159% YoY revenue growth for fiscal 2020 

The company announced the financial results for fiscal 2020 ended February 28, 2021. Revenue was $262,805, representing 159% YoY increase. Net loss was $2.297 million or $0.03 per share. 

Upsell said, “The Company achieved a number of key milestones this year, is transitioning efficiently into its commercialization stage from research and development and our IP has expanded to fulfill a number of our core business drivers. Momentum is building, and we are pleased to see sales growth in our key business lines including cannabis and nutraceuticals with rapid movement with our partners at McMaster University on the COVID-19 vaccine candidate.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

SinglePoint Inc.’s (OTCMKTS: SING) Subsidiary BOX Pure Air Receives $2 Million Purchase Order for Clean Indoor Air Solutions

Published

on

SinglePoint Inc.’s (OTCMKTS: SING) subsidiary BOX Pure Air has announced that it has received a purchase order of almost $2 million from a school district in North Carolina to implement a clean indoor air solution using AirBox Apex, Mesa, and Peak units. BOX Pure Air is committed to creating clean and safe indoor air zones to enhance air quality and overall health. 

BOX Pure Air to deploy AIRBOX AIR PURIFIERS in schools

The school district in North Carolina is deploying a comprehensive campus solution tailored to the individual needs of the different indoor rooms unit combinations. AIRBOX AIR PURIFIERS are a business-grade, made-in-the-USA system that blends Certified HEPA filtering with high speed to alter the active indoor air circulation for a complete pathogen hardening solution. AirBox is high-quality, low-maintenance, user-friendly, with a five-year guarantee on all products.

CEO of BOX PureAir, Ryan Cowell, said, “The team at BOX Pure Air, have collaborated with this district since the early spring of 2021 in order to create safe indoor air environments. We are pleased with their decision to move forward with our Made in the USA Commercial AIRBOX Air Purification Units that utilize Certified HEPA filtration distributed by BOX Pure Air. This is the first full implementation order of an entire district and although this district represents less than 25 schools, we are in active discussions with several other individual schools and small, medium and large school districts.” 

Demand for clean indoor air solutions growing 

SinglePoint CEO commented, “This is an exciting time for the SinglePoint shareholders and stakeholders as we are beginning to see growing demand for clean indoor air solutions and we are well-positioned to take advantage of that increasing demand to create clean indoor air environments at school, at work and at home. This initial full implementation of a school district reaffirms our decision to acquire BOX Pure Air and the initial go-to-market strategy which was and still is primarily focused on our nation’s schools as they look for solutions to keep schools open and provide clean air for students and educators.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Charlotte’s Web Holdings Inc (OTCMKTS: CWBHF) Reorganizes for Agility, Growth, and Cash Generation

Published

on

Charlotte’s Web Holdings Inc (OTCMKTS: CWBHF) recently completed its reorganization to drive agility and growth as it prepares to launch new products. Charlotte Web is a leading company that develops and distributes the world’s most trusted Hemp Extract. 

Charlotte’s Web will return a positive cash flow in 2022

The company plans to launch various channels and markets to return a positive cash flow this year. These changes follow the new leadership announcement released on December 16, 2021. 

During a press conference, Jacques Tortoroli, the company’s Chief Executive Officer, stated that Charlotte’s Web moved financially to decrease the costs and tie compensation more to equity growth to better align with shareholder interests and accelerate its return to positive cash flow in 2022.  

The company transitioned into a horizontal organizational structure to increase its workers’ decision-making and accountability. Its recent mission and culture based on compassion was initially an organization that helped a little girl in need and eventually helped thousands of consumers.

 Charlotte’s Web founding culture and mission established the improvement of consumers’ health via the healing powers of botanicals with compassion and science. The company’s reorganization marks a return to its initial principles of a dynamic, fast-moving entrepreneurial organization. 

Charlotte’s Web has come up with growth initiatives for the year

As one of the leading brands in the country, the company aims to continue its incremental market share gains this year. Currently, the company has created various growth initiatives for 2022, such as a new focus on e-commerce consumer experience and social media marketing strategies, among others. 

Charlotte’s Web Holding Inc is one of the leading companies in the CBD market. Based in Denver, Colorado, the company extracts wellness products under a family of brands such as Charlotte’s Web, CBD Medic, and CBD Clinic. 

The company develops premium quality products that start with proprietary hemp genetics that are 100-percent American farm-grown and manufactured into hemp extracts containing naturally occurring phytocannabinoids and other beneficial hemp compounds. 

The Company’s CW Labs R&D division advances hemp science at two centers of excellence in Louisville, Colorado, and the Hauptmann Woodward Research Institute at the University at Buffalo, part of the State University of New York (SUNY) network. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Skye Bioscience Inc (OTCMKTS: SKYE) Issues Shareholder Letter Outlining Progress Update and Business Outlook for 2022

Published

on

Punit Dhillon, Skye Bioscience Inc (OTCMKTS: SKYE) Chief Executive Officer recently wrote a letter to the company’s shareholders detailing the company’s current progress and business outlook for the year 2022. 

Contents of the letter

The pharmaceutical company develops proprietary, synthetic, cannabinoid-derived molecules that assist in treating illnesses with significant unmet needs. The letter also addressed collaborators and partners who have supported the company since its inception. 

Dhillon began the letter by showing his gratitude to the shareholder’s and partners’ support since the company’s inception. He also thanked them for their financial support and dedication in bringing the company’s novel cannabinoid-based compounds as a potential new class of medicines.

Skye’s mission, has over the past 18 months, been to demonstrate its novel cannabinoid-based compound for glaucoma as an essential medicine for patients. Dhillon added that the company recognized its contributions to the global pharmaceutical market that is constantly changing. 

 However, these changes only challenged it to stay one step ahead of the curve in terms of innovation. As a result, the company constantly focuses on consistently executing its goals until meaningful progress is received.

Last year was significant for Skye Bioscience’s actual progress; it strengthened its team and completed the preclinical development necessary to advance SBI-100 into the clinic.

Skye Bioscience plans to conduct a Phase I study for SBI-100 in 2022

The letter outlined the company’s progress for the year 2021 and the plans it had in store for 2022. Dhillon stated that the company planned to achieve milestones such as completing Phase I study to establish safety and tolerability of SBI-100 in humans and the development of a drug development platform to uncover novel molecules of action capable of modulating the endocannabinoid system, among others. 

Skye Bioscience Inc. is a leading biopharmaceutical company that aims at unlocking the pharmaceutical potential of cannabinoids via the advancement of its proprietary cannabinoid-derived molecules.

The aim is to utilize the compound to treat diseases with significant unmet needs. The company’s lead program, SBI-100, is focused on treating glaucoma, a disease with no cure and the world’s leading cause of irreversible blindness and others. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories